Whipplewood Advisors LLC Has $2.33 Million Stock Holdings in GSK plc (NYSE:GSK)

Whipplewood Advisors LLC grew its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 4,367.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 60,131 shares of the pharmaceutical company's stock after acquiring an additional 58,785 shares during the quarter. Whipplewood Advisors LLC's holdings in GSK were worth $2,329,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Brighton Jones LLC acquired a new position in GSK during the 4th quarter valued at about $528,000. Perigon Wealth Management LLC boosted its holdings in shares of GSK by 5.0% in the fourth quarter. Perigon Wealth Management LLC now owns 10,115 shares of the pharmaceutical company's stock valued at $338,000 after acquiring an additional 484 shares in the last quarter. Caprock Group LLC boosted its holdings in shares of GSK by 7.7% in the fourth quarter. Caprock Group LLC now owns 19,942 shares of the pharmaceutical company's stock valued at $684,000 after acquiring an additional 1,424 shares in the last quarter. Spire Wealth Management acquired a new position in shares of GSK during the fourth quarter valued at approximately $77,000. Finally, CENTRAL TRUST Co lifted its position in GSK by 5.6% in the fourth quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company's stock worth $262,000 after purchasing an additional 414 shares during the period. Institutional investors own 15.74% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on GSK shares. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research report on Tuesday. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. Morgan Stanley began coverage on GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Wall Street Zen downgraded GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Finally, BNP Paribas assumed coverage on shares of GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price for the company. One analyst has rated the stock with a sell rating, nine have given a hold rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, GSK presently has a consensus rating of "Hold" and a consensus target price of $37.38.

GSK Stock Performance

GSK traded up $0.31 on Thursday, hitting $41.11. The company had a trading volume of 3,203,636 shares, compared to its average volume of 4,830,240. The stock has a market cap of $84.82 billion, a price-to-earnings ratio of 25.86, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The company's fifty day moving average price is $37.48 and its 200 day moving average price is $36.28. GSK plc has a 1-year low of $31.72 and a 1-year high of $44.67.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. The company had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. The business's quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the company earned $0.43 earnings per share. Equities analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be given a $0.4216 dividend. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.10%. The ex-dividend date of this dividend is Friday, May 16th. GSK's payout ratio is currently 86.60%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.